JP2015514083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514083A5 JP2015514083A5 JP2015503245A JP2015503245A JP2015514083A5 JP 2015514083 A5 JP2015514083 A5 JP 2015514083A5 JP 2015503245 A JP2015503245 A JP 2015503245A JP 2015503245 A JP2015503245 A JP 2015503245A JP 2015514083 A5 JP2015514083 A5 JP 2015514083A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- acid
- omega
- dha
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 55
- 239000000203 mixture Substances 0.000 claims 30
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 23
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 23
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 22
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 22
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 20
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 19
- -1 omega-3 fatty acid ester Chemical class 0.000 claims 18
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 6
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 claims 6
- 206010000891 acute myocardial infarction Diseases 0.000 claims 5
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 125000004494 ethyl ester group Chemical group 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 229920001983 poloxamer Polymers 0.000 claims 4
- 229960000502 poloxamer Drugs 0.000 claims 4
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical group CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 claims 3
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 claims 3
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 claims 3
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 claims 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N D-limonene Natural products CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims 3
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 3
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 3
- 229960004488 linolenic acid Drugs 0.000 claims 3
- 239000006014 omega-3 oil Substances 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 229950008882 polysorbate Drugs 0.000 claims 3
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 2
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 claims 2
- 235000019502 Orange oil Nutrition 0.000 claims 2
- 208000007718 Stable Angina Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000010502 orange oil Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- 235000007586 terpenes Nutrition 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 229930003802 tocotrienol Natural products 0.000 claims 2
- 239000011731 tocotrienol Substances 0.000 claims 2
- 235000019148 tocotrienols Nutrition 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- 125000000545 (4R)-limonene group Chemical group 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 229920002511 Poloxamer 237 Polymers 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 206010002895 aortic dissection Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 1
- 230000010339 dilation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- FPXCJLDGCPZYBW-UHFFFAOYSA-N henicosa-1,3,5,7,9-pentaene Chemical compound CCCCCCCCCCCC=CC=CC=CC=CC=C FPXCJLDGCPZYBW-UHFFFAOYSA-N 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 235000021301 omega-3 deficiency Nutrition 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618161P | 2012-03-30 | 2012-03-30 | |
| US61/618,161 | 2012-03-30 | ||
| PCT/US2013/030211 WO2013148136A1 (en) | 2012-03-30 | 2013-03-11 | Omega-3 fatty acid ester compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514083A JP2015514083A (ja) | 2015-05-18 |
| JP2015514083A5 true JP2015514083A5 (OSRAM) | 2016-05-12 |
| JP6359517B2 JP6359517B2 (ja) | 2018-07-18 |
Family
ID=47998519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503245A Expired - Fee Related JP6359517B2 (ja) | 2012-03-30 | 2013-03-11 | ω−３脂肪酸エステル組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (9) | US9302016B2 (OSRAM) |
| EP (2) | EP2830602B1 (OSRAM) |
| JP (1) | JP6359517B2 (OSRAM) |
| KR (1) | KR102193214B1 (OSRAM) |
| CN (2) | CN109966279A (OSRAM) |
| AU (1) | AU2013240427B2 (OSRAM) |
| CA (1) | CA2867168A1 (OSRAM) |
| CO (1) | CO7121328A2 (OSRAM) |
| DK (1) | DK3072510T3 (OSRAM) |
| ES (1) | ES2741560T3 (OSRAM) |
| HK (1) | HK1204978A1 (OSRAM) |
| HR (1) | HRP20191392T1 (OSRAM) |
| IL (3) | IL249821B (OSRAM) |
| IN (1) | IN2014DN08449A (OSRAM) |
| MX (1) | MX359711B (OSRAM) |
| MY (1) | MY189576A (OSRAM) |
| PT (1) | PT3072510T (OSRAM) |
| RU (1) | RU2633862C2 (OSRAM) |
| WO (1) | WO2013148136A1 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SI2443246T1 (en) | 2009-06-15 | 2018-05-31 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| EP2646013A4 (en) | 2010-11-29 | 2014-03-26 | Amarin Pharma Inc | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| SG10201701004RA (en) | 2012-01-06 | 2017-04-27 | Omthera Pharmaceuticals Inc | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
| MY189576A (en) | 2012-03-30 | 2022-02-17 | Micelle Biopharma Inc | Omega-3 fatty acid ester compositions |
| WO2014005013A2 (en) | 2012-06-29 | 2014-01-03 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| WO2015011724A2 (en) | 2013-07-22 | 2015-01-29 | Kms Health Center Pvt Ltd | A novel omega -3 fatty acid composition with a plant extract |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015066512A1 (en) * | 2013-10-31 | 2015-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2016046680A2 (en) * | 2014-09-27 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of liver metabolic diseases |
| MA40846A (fr) * | 2014-10-10 | 2017-09-05 | Sancilio & Company Inc | Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques |
| RU2709612C2 (ru) * | 2015-01-21 | 2019-12-19 | Мотида Фармасьютикал Ко., Лтд. | САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ |
| MA41611A (fr) | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
| DE102015106095A1 (de) * | 2015-04-21 | 2016-10-27 | K. D. Pharma Bexbach Gmbh | Neue Anwendung von Omega-3-Fettsäure(n) |
| WO2017033119A1 (en) * | 2015-08-25 | 2017-03-02 | Rao M Surya | Compositions and methods for the treatment of liver metabolic diseases |
| CN116492339A (zh) * | 2015-11-13 | 2023-07-28 | 深圳君圣泰生物技术有限公司 | 一种组合物及其用途、药物制剂 |
| EP4218736A3 (en) * | 2015-12-18 | 2023-10-18 | Afimmune Limited | Compositions comprising 15-hepe |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| ES2836729T3 (es) * | 2016-03-16 | 2021-06-28 | Golden Omega Norway As | Polvos y comprimidos que contienen derivados de ácidos grasos omega-3 y procedimiento para su producción |
| US11241408B2 (en) | 2016-08-12 | 2022-02-08 | Pharmako Biotechnologies Pty Limited | Omega-3 compositions and methods relating thereto |
| AU2017329957B2 (en) | 2016-09-21 | 2020-05-07 | Avexxin As | Pharmaceutical composition |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| CN108354919A (zh) * | 2017-12-29 | 2018-08-03 | 广东海洋大学 | 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| HUE067138T2 (hu) | 2018-09-24 | 2024-10-28 | Amarin Pharmaceuticals Ie Ltd | Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban |
| BR112021015145A2 (pt) * | 2019-02-01 | 2021-09-28 | Mars, Incorporated | Composição alimentar felina |
| CN116350616A (zh) | 2019-11-12 | 2023-06-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| WO2021183749A1 (en) | 2020-03-12 | 2021-09-16 | Sancilio Fred D | A composition comprising docosahexaenoic acid and egg yolk suitable for sickle cell disease treatment |
| US20230398088A1 (en) * | 2020-10-30 | 2023-12-14 | The Trustees Of The University Of Pennsylvania | Lipid Prophylactic Brain Injury Treatment |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513008A (en) | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
| US4992476A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Skin cleansing and moisturizing composition and method of using and preparing same |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| WO1990009168A1 (en) | 1989-02-16 | 1990-08-23 | National Research Development Corporation | Dispensing device |
| US5320798A (en) | 1993-02-17 | 1994-06-14 | Exxon Chemical Patents, Inc. | Method for processing polyolefins at high shear rates |
| US5585192A (en) | 1995-10-02 | 1996-12-17 | Eastman Chemical Company | Waterborne polyolefin adhesion promoter |
| WO1999029316A1 (en) * | 1997-12-10 | 1999-06-17 | Severson, Mary, L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| US6121210A (en) | 1998-03-12 | 2000-09-19 | Dap Products Inc. | Foamable silicone oil compositions and methods of use thereof |
| IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
| IL148685A0 (en) | 1999-09-21 | 2002-09-12 | Rtp Pharma Inc | Surface modified particulate compositions of biologically active substances |
| NO313076B1 (no) | 1999-12-28 | 2002-08-12 | Pronova Biocare As | Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav |
| KR100441167B1 (ko) | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | 마이크로에멀젼 예비 농축액 조성물 |
| US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
| US20060165735A1 (en) | 2002-06-18 | 2006-07-27 | Abril Jesus R | Stable emulsions of oils in aqueous solutions and methods for producing same |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| JP2006505583A (ja) | 2002-10-25 | 2006-02-16 | フォーミックス エルティーディー． | 化粧剤および医薬用フォーム |
| BRPI0412975A (pt) | 2003-08-25 | 2006-10-03 | Foamix Ltd | espuma penetrante para uso farmacêutico |
| CA2545752C (en) | 2003-11-12 | 2013-03-26 | Children's Medical Center Corporation | Treatment and prevention of liver disease associated with parenteral nutrition (pn) |
| SE0303513D0 (sv) | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| JP2007526943A (ja) | 2004-03-04 | 2007-09-20 | エイチティーエル ハイ − テック リピッズ リミテッド | 構造化されたトリグリセリド類およびそれを含むエマルション類 |
| CN101043884A (zh) | 2004-07-01 | 2007-09-26 | 谢彭斯眼科研究公司 | 用于治疗眼部疾病和病症的组合物和方法 |
| US8377494B2 (en) | 2004-07-22 | 2013-02-19 | Aquanova Ag | Concentrates of active agents, such as W-3 fatty acids, and polysorbate |
| ITRM20040395A1 (it) * | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
| KR20070038553A (ko) | 2004-08-06 | 2007-04-10 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 신규한 스타틴 약제학적 조성물 및 관련된 치료방법 |
| SG155189A1 (en) | 2004-08-06 | 2009-09-30 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment |
| WO2006019140A1 (ja) * | 2004-08-18 | 2006-02-23 | Mochida Pharmaceutical Co., Ltd. | ゼリー組成物 |
| JPWO2006022291A1 (ja) | 2004-08-27 | 2008-05-08 | 千寿製薬株式会社 | ドライアイ治療用点眼液 |
| US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| KR20070108945A (ko) | 2005-03-08 | 2007-11-13 | 릴라이언트 파마슈티컬스 인코퍼레이티드 | 스타틴과 오메가-3 지방산 및 그 조합물을 이용한 치료 |
| US20060223737A1 (en) | 2005-03-25 | 2006-10-05 | L'oreal | Foaming O/W emulsion and use thereof in cosmetics |
| US9968120B2 (en) | 2006-05-17 | 2018-05-15 | Dsm Nutritional Products Ag | Homogenized formulations containing microcapsules and methods of making and using thereof |
| BRPI0616791A2 (pt) | 2005-09-29 | 2011-07-05 | Arena Pharm Inc | composições farmacêuticas de um modulador de receptor de serotonina de 5-ht 2a útil para o tratamento de distúrbios relacionados a este |
| US20070104779A1 (en) | 2005-11-07 | 2007-05-10 | Rongen Roelof M | Treatment with omega-3 fatty acids and products thereof |
| EP1946755B1 (en) * | 2005-11-11 | 2017-03-15 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
| DE602006016328D1 (de) | 2005-11-22 | 2010-09-30 | Nestec Sa | Öl-in-wasser-emulsion und ihre verwendung zur abgabe einer funktionalität |
| WO2007075841A1 (en) | 2005-12-20 | 2007-07-05 | Cenestra, Llc | Omega 3 fatty acid formulations |
| CN101553136A (zh) * | 2006-09-06 | 2009-10-07 | 可口可乐公司 | 稳定的多不饱和脂肪酸乳液及用于防止、抑制或降低多不饱和脂肪酸在乳液中降解的方法 |
| US20080058418A1 (en) * | 2006-09-06 | 2008-03-06 | The Coca-Cola Company | Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion |
| CN101534796B (zh) | 2006-10-31 | 2014-09-17 | 株式会社钟化 | 含有生理活性物质的粒状组合物及其制备方法 |
| US20080306154A1 (en) | 2006-11-03 | 2008-12-11 | My Svensson | Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids |
| WO2009009040A2 (en) | 2007-07-06 | 2009-01-15 | Baum Seth J | Fatty acid compositions and methods of use |
| US20090182049A1 (en) | 2008-01-16 | 2009-07-16 | Joar Arild Opheim | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans |
| GB0813599D0 (en) * | 2008-07-24 | 2008-09-03 | Pharma Marine As | Method |
| US20100062057A1 (en) | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
| CN101380358B (zh) | 2008-10-14 | 2012-12-19 | 沈阳药科大学 | 精制紫苏籽油脂肪乳注射液及制备工艺 |
| WO2010119319A1 (en) | 2009-03-09 | 2010-10-21 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof |
| US20110071090A1 (en) * | 2009-03-11 | 2011-03-24 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle |
| KR101759353B1 (ko) | 2009-04-17 | 2017-07-18 | 나타크 파마 에스.엘 | 오메가-3 지방산이 풍부하고 피탄산 함량이 적은 조성물 |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| JP5313343B2 (ja) * | 2009-05-22 | 2013-10-09 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
| US9480645B2 (en) | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
| US20110045050A1 (en) | 2009-08-24 | 2011-02-24 | Atrium Medical Corporation | Nanoemulsion formulations for direct delivery |
| ES2661812T3 (es) | 2009-10-16 | 2018-04-04 | Mochida Pharmaceutical Co., Ltd. | Composiciones |
| WO2011048493A1 (en) * | 2009-10-23 | 2011-04-28 | Pronova Biopharma Norge As | Coated capsules and tablets of a fatty acid oil mixture |
| CN102695413A (zh) | 2009-11-10 | 2012-09-26 | 麦赛尔控股有限公司 | 稳定的脂肪酸的制剂 |
| AR082930A1 (es) * | 2010-09-08 | 2013-01-16 | Pronova Biopharma Norge As | Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina |
| US20140017308A1 (en) * | 2010-09-08 | 2014-01-16 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin |
| JP2013537185A (ja) | 2010-09-08 | 2013-09-30 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 遊離酸の形のｅｐａおよびｄｈａを含む脂肪酸油混合物と界面活性剤とスタチンとを含む組成物 |
| WO2012037311A1 (en) | 2010-09-17 | 2012-03-22 | Maine Natural Health, Inc. | Compositions containing omega-3 oil and uses thereof |
| WO2012037328A2 (en) | 2010-09-17 | 2012-03-22 | Maine Natural Health, Inc. | Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof |
| CN104394850A (zh) | 2012-02-16 | 2015-03-04 | 布莱特赛德创新有限公司 | 膳食和营养组合物及应用的方法 |
| MY189576A (en) | 2012-03-30 | 2022-02-17 | Micelle Biopharma Inc | Omega-3 fatty acid ester compositions |
-
2013
- 2013-03-11 MY MYPI2014002698A patent/MY189576A/en unknown
- 2013-03-11 CA CA2867168A patent/CA2867168A1/en not_active Abandoned
- 2013-03-11 JP JP2015503245A patent/JP6359517B2/ja not_active Expired - Fee Related
- 2013-03-11 ES ES16165946T patent/ES2741560T3/es active Active
- 2013-03-11 EP EP13712624.9A patent/EP2830602B1/en active Active
- 2013-03-11 IN IN8449DEN2014 patent/IN2014DN08449A/en unknown
- 2013-03-11 CN CN201811562944.2A patent/CN109966279A/zh active Pending
- 2013-03-11 HK HK15105834.2A patent/HK1204978A1/xx unknown
- 2013-03-11 EP EP16165946.1A patent/EP3072510B1/en active Active
- 2013-03-11 CN CN201380027275.8A patent/CN104321053A/zh active Pending
- 2013-03-11 PT PT16165946T patent/PT3072510T/pt unknown
- 2013-03-11 WO PCT/US2013/030211 patent/WO2013148136A1/en not_active Ceased
- 2013-03-11 IL IL24982113A patent/IL249821B/xx active IP Right Grant
- 2013-03-11 DK DK16165946.1T patent/DK3072510T3/da active
- 2013-03-11 KR KR1020147029132A patent/KR102193214B1/ko not_active Expired - Fee Related
- 2013-03-11 AU AU2013240427A patent/AU2013240427B2/en not_active Ceased
- 2013-03-11 RU RU2014141406A patent/RU2633862C2/ru not_active IP Right Cessation
- 2013-03-11 MX MX2014011596A patent/MX359711B/es active IP Right Grant
-
2014
- 2014-08-11 US US14/456,731 patent/US9302016B2/en not_active Expired - Fee Related
- 2014-08-11 US US14/456,750 patent/US9302017B2/en not_active Expired - Fee Related
- 2014-09-23 IL IL234814A patent/IL234814A/en active IP Right Grant
- 2014-10-30 CO CO14240867A patent/CO7121328A2/es unknown
-
2015
- 2015-07-24 US US14/808,847 patent/US9364560B2/en not_active Expired - Fee Related
- 2015-07-24 US US14/808,876 patent/US9364562B2/en not_active Expired - Fee Related
- 2015-07-24 US US14/808,809 patent/US9364558B2/en not_active Expired - Fee Related
- 2015-07-24 US US14/808,835 patent/US9364559B2/en not_active Expired - Fee Related
- 2015-07-24 US US14/808,777 patent/US9370585B2/en not_active Expired - Fee Related
- 2015-07-24 US US14/808,866 patent/US9364561B2/en not_active Expired - Fee Related
- 2015-07-24 US US14/808,871 patent/US9375490B2/en not_active Expired - Fee Related
-
2016
- 2016-12-28 IL IL249821A patent/IL249821A0/en unknown
-
2019
- 2019-08-01 HR HRP20191392TT patent/HRP20191392T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514083A5 (OSRAM) | ||
| HRP20191392T1 (hr) | Pripravci estera omega-3 masnih kiselina | |
| ES2826201T3 (es) | Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados | |
| JP6173437B2 (ja) | スタチン及びω−３脂肪酸の組成物 | |
| CA2803558C (en) | .omega.3 fatty acid compound preparation | |
| US20210128510A1 (en) | Self-emulsifying composition of omega3 fatty acid | |
| US20140107199A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| US9895333B2 (en) | Enhanced bioavailability of polyunsaturated fatty acids | |
| JP2013521310A5 (OSRAM) | ||
| JP2013508296A5 (OSRAM) | ||
| JP2014512351A5 (OSRAM) | ||
| CA2905671A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| JP2016501248A5 (OSRAM) | ||
| JP6469261B2 (ja) | 多価不飽和遊離脂肪酸を含むミリカプセル製剤 | |
| WO2009059717A2 (en) | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use | |
| WO2014095628A1 (en) | Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa) | |
| MX2011001419A (es) | Tratamiento a largo plazo de deficiencia cardiaca sintomatica. | |
| RU2017145265A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| WO2015200563A1 (en) | Enhanced bioavailability of polysaturated fatty acids | |
| NZ732235A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| JP2020090448A (ja) | アレルギー性結膜炎予防又は治療剤 | |
| Fallon et al. | 21 Use of Parenteral Fish Oil in the Management of IF-Associated Liver Disease | |
| JP2017522278A5 (OSRAM) |